Triage in scarce, established treatments is often possible when the natural history of the disease, medication effects, and status of the patient are taken into account. Yet, with experimental treatments, few of these factors can be determined vis-à-vis the effect of the drug—one loses the ability to discern the patients likely to benefit. With this inability to properly triage, the consequences of misuse may be 3-fold: poorer outcomes for the “treated” severely ill population, missed opportunities for realistically treatable patients, and a possible induction of resistance that bears worse outcomes for future patients. The multinational setting of the epidemic magnifies these unknown inequalities. The proprietary nature of unregistered medications amplifies the strain between private supply and public demand. Possible secondary gains demand regulation that can never be attained within the epidemic time frame. These potential difficulties in transitional accountability bring to mind Pfizer's meningococcal meningitis trial, in which 200 Nigerian children were administered dose-reduced ceftriaxone or an unregistered medication, trovafloxacin, without informed consent. This led to a $75 million settlement, international outrage, and 11 deaths, all of which underscore physicians' responsibilities in human research (7).